Every 424B that Conexeu Sciences Inc. (CNXU) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CNXU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNXU filings page.
Conexeu Sciences Inc. (CNXU) supplements its prospectus for 9,481,123 shares of common stock and adds disclosures about recent issuances.
On October 15, 2026, the company issued 1,333,333 units at $3.00 each for gross proceeds of $3,999,999. Each unit includes one share and a warrant to buy one share at $3.00, exercisable for 24 months. It also issued 250,000 special warrants at $3.00 each for gross proceeds of $750,000; they convert automatically into one share and one warrant upon the earlier of receipt of the qualifying British Columbia prospectus or February 16, 2027. Proceeds from these issuances are intended for working capital and general corporate purposes.
A separate subscription for 83,334 units, valued at $250,002, is held in escrow pending stockholder approval; without approval, the securities will not be issued and the funds will be returned. The company also agreed to file a continuous resale registration statement for the private-placement shares and warrant shares by the 35th calendar day after October 15, 2026, excluding affiliate-held shares; late filing would require cash partial liquidated damages equal to 2.0% of a subscriber’s aggregate subscription price.
Conexeu Sciences Inc. (CNXU) has registered 9,481,123 shares of common stock under an existing Form S-1 and is updating its prospectus with results for the quarter ended July 31, 2026.
The company, which has no commercial revenue and is developing its CXU™ regenerative skin therapy, reported a quarterly net loss of $7.7 million and a nine‑month net loss of $11.7 million, sharply higher than the prior year. Operating expenses reached $7.7 million for the quarter, driven mainly by consulting, business development, and related‑party management compensation. Cash and cash equivalents were $1.97 million (total cash and restricted cash $2.21 million) against $1.27 million in current liabilities, and management states that there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Shares outstanding rose to 27.4 million at July 31, 2026 and 28.2 million by September 10, 2026, reflecting private placements, warrant inducement exercises, and share‑based payments.
Conexeu Sciences Inc. (CNXU) files a prospectus supplement covering 9,481,123 shares of common stock under its Form S-1 and incorporates a new current report. The update discloses that from June 18, 2026 through September 4, 2026, the company issued 1,448,368 unregistered shares of common stock and 202,500 unregistered common stock purchase warrants, exceeding 5% of its outstanding shares since its last periodic report.
The largest single transaction was on September 4, 2026, when 762,608 shares were issued upon warrant exercises at $2.30 per share for $1,753,998.40 in gross proceeds, intended for working capital and general corporate purposes. Additional smaller issuances compensated consultants and directors and included June 18, 2026 warrant-related issuances generating approximately $162,202.50 plus a 250,000-share exercise at $0.001 per share. CNXU’s shares trade on the Nasdaq Capital Market at $4.25 per share as of September 10, 2026.
Conexeu Sciences Inc. registers 9,481,123 shares of Common Stock via a prospectus supplement to its Form S-1. This supplement incorporates and attaches the Company’s Form 8-K (June 9, 2026) and Form 10-Q (quarter ended April 30, 2026).
The supplement states the Company’s shares trade on Nasdaq under the symbol CNXU and cites a closing price of $9.82 on June 15, 2026. The filing discloses recent warrant activity: issuance and exercises tied to an incentive program and incremental issuances that affected shares outstanding.
Shares outstanding were 26,758,330 as of June 10, 2026. The supplement updates the Prospectus and must be read with the Prospectus for full terms and risk disclosures.